

Michael J Birrer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/700580/publications.pdf>

Version: 2024-02-01

111
papers

7,269
citations

94269

37
h-index

58464

82
g-index

138
all docs

138
docs citations

138
times ranked

12557
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk stratification after recurrence of human papillomavirus (HPV) -related and non-HPV -related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. <i>Head and Neck</i> , 2021, 44, 158.	0.9	3
2	Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-0752 in recurrent endometrial cancer. <i>International Journal of Cancer</i> , 2020, 147, 413-422.	2.3	31
3	Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. <i>American Journal of Clinical Pathology</i> , 2020, 153, 149-155.	0.4	7
4	Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. <i>Clinical Cancer Research</i> , 2020, 26, 1288-1296.	3.2	29
5	The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 509-519.	1.1	34
6	Overexpression of enhancer of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2020, 156, 423-429.	0.6	23
7	Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology's Gynecologic Oncology Group Study 240 (NCT 00803062). <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2363-2370.	1.9	15
8	Inhibition of the Wnt/ β -catenin pathway enhances antitumor immunity in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091379.	1.4	21
9	Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6417-6428.	3.2	39
10	Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. <i>Gynecologic Oncology Reports</i> , 2019, 29, 118-122.	0.3	17
11	Real-Time Single-Walled Carbon Nanotube-Based Fluorescence Imaging Improves Survival after Debulking Surgery in an Ovarian Cancer Model. <i>ACS Nano</i> , 2019, 13, 5356-5365.	7.3	70
12	Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice. <i>Oncologist</i> , 2019, 24, 576-579.	1.9	0
13	Olaparib and β -specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , 2019, 20, 570-580.	5.1	191
14	Antibody-Drug Conjugate-Based Therapeutics: State of the Science. <i>Journal of the National Cancer Institute</i> , 2019, 111, 538-549.	3.0	257
15	Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. <i>Cell Reports</i> , 2019, 27, 255-268.e6.	2.9	38
16	Biomarkers in ovarian cancer: To be or not to be. <i>Cancer</i> , 2019, 125, 4563-4572.	2.0	38
17	Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. <i>Clinical Cancer Research</i> , 2019, 25, 1727-1736.	3.2	39
18	Variation in resource utilization associated with the surgical management of ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 587-593.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3928-3940.	3.2	35
20	FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. <i>Future Oncology</i> , 2018, 14, 1669-1678.	1.1	55
21	Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. <i>Oncologist</i> , 2018, 23, 697-703.	1.9	12
22	Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 2749-2757.	3.2	37
23	A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. <i>Future Oncology</i> , 2018, 14, 123-136.	1.1	60
24	ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. <i>Cancers</i> , 2018, 10, 464.	1.7	28
25	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. <i>Journal of Pathology</i> , 2018, 246, 459-469.	2.1	23
26	Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR1 \pm)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 46-52.	0.6	48
27	ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. <i>Genes and Development</i> , 2017, 31, 318-332.	2.7	307
28	Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents. <i>Journal of the American Chemical Society</i> , 2017, 139, 3033-3044.	6.6	74
29	Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2017, 146, 137-145.	0.6	4
30	Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor 1 \pm -targeting antibody-drug conjugate, in patients with solid tumors. <i>Cancer</i> , 2017, 123, 3080-3087.	2.0	94
31	Early tumor detection afforded by in vivo imaging of near-infrared II fluorescence. <i>Biomaterials</i> , 2017, 134, 202-215.	5.7	100
32	Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	74
33	High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2017, 146, 247-253.	0.6	23
34	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
35	A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 144, 101-106.	0.6	7
36	Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 147, 396-401.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 147, 648-653.	0.6	21
38	Characterization of folate receptor alpha (FR α) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FR α -targeting antibody-drug conjugate mirvetuximab soravtansine. <i>Gynecologic Oncology</i> , 2017, 147, 402-407.	0.6	73
39	Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). <i>Lancet</i> , The, 2017, 390, 1654-1663.	6.3	424
40	An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. <i>Gynecologic Oncology</i> , 2017, 147, 243-249.	0.6	61
41	Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 177-178.	2.0	14
42	Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. <i>Nature Communications</i> , 2017, 8, 2166.	5.8	71
43	Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1112-1118.	0.8	158
44	Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. <i>Journal of Clinical Investigation</i> , 2017, 128, 589-606.	3.9	105
45	Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 5535-5535.	0.8	9
46	Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts. <i>Journal of Clinical Oncology</i> , 2017, 35, 5547-5547.	0.8	7
47	Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 5553-5553.	0.8	5
48	Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and <i>POLR2A</i> -mutated recurrent or persistent endometrial cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5615-TPS5615.	0.8	6
49	Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target. <i>Oncotarget</i> , 2017, 8, 96482-96495.	0.8	15
50	The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2017, 35, 241-241.	0.8	0
51	Clinical characterization of long term survivors (LTS) in ovarian cancer (OC): Results of a propensity score matched (PSM) analysis of the international prospective tumor bank for ovarian cancer (TOC) Tj ETQq1 1 0.784314 rgBT /Overl		
52	Harnessing IMGN853-mediated cell cytotoxicity response by modulating FR α expression in ovarian cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, e17061-e17061.	0.8	0
53	The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2017, 35, e18195-e18195.	0.8	0
54	FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FR α)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5607-TPS5607.	0.8	3

#	ARTICLE	IF	CITATIONS
55	CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. PLoS ONE, 2016, 11, e0156595.	1.1	38
56	The Doppelgänger Effect: Hidden Duplicates in Databases of Transcriptome Profiles. Journal of the National Cancer Institute, 2016, 108, djw146.	3.0	18
57	A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecologic Oncology, 2016, 142, 62-69.	0.6	70
58	Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer, 2016, 122, 3297-3306.	2.0	2
59	Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities. Gynecologic Oncology, 2016, 142, 248-254.	0.6	34
60	Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. Targeted Oncology, 2016, 11, 317-327.	1.7	10
61	Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2016, 141, 43-48.	0.6	21
62	Targeting the Nuclear Import Receptor Kpn1 ²¹ as an Anticancer Therapeutic. Molecular Cancer Therapeutics, 2016, 15, 560-573.	1.9	57
63	Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. JAMA Oncology, 2016, 2, 370.	3.4	88
64	Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. New England Journal of Medicine, 2016, 374, 738-748.	13.9	303
65	Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncology, 2016, 2, 482.	3.4	576
66	Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin-paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.. Journal of Clinical Oncology, 2016, 34, 5521-5521.	0.8	5
67	Real-time single-walled nanotube (SWNT)-based imaging system to improve tumor detection and survival in ovarian cancer preclinical model.. Journal of Clinical Oncology, 2016, 34, 5530-5530.	0.8	1
68	A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.. Journal of Clinical Oncology, 2016, 34, 5555-5555.	0.8	7
69	IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).. Journal of Clinical Oncology, 2016, 34, 5567-5567.	0.8	3
70	A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC).. Journal of Clinical Oncology, 2016, 34, 5569-5569.	0.8	3
71	Tumor responses and preliminary survival data in a phase II trial of ofranergene obadenovec (VB-111) combined with paclitaxel in patients with recurrent platinum resistant ovarian cancer.. Journal of Clinical Oncology, 2016, 34, 5551-5551.	0.8	0
72	Quality of life among long-term ovarian cancer survivors.. Journal of Clinical Oncology, 2016, 34, e21570-e21570.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. <i>Clinical Cancer Research</i> , 2015, 21, 4960-4969.	3.2	62
74	Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv442.	3.0	13
75	Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. <i>Gynecologic Oncology</i> , 2015, 136, 246-253.	0.6	104
76	AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4418-27.	3.3	45
77	Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer. <i>Cancer Cell</i> , 2015, 28, 7-9.	7.7	15
78	Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 374-381.	1.2	22
79	Translational Impact of Nanoparticle-Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 808-818.	3.2	70
80	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
81	Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. <i>Journal of Controlled Release</i> , 2015, 220, 358-367.	4.8	15
82	Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin-paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5505-5505.	0.8	18
83	Preliminary single agent activity of IMGN853, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5518-5518.	0.8	7
84	Phase 1 study of IMGN853, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5558-5558.	0.8	12
85	A phase 1 study optimizing the dosing of olaparib tablet formulation combined with cediranib in recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5559-5559.	0.8	2
86	A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5571-5571.	0.8	6
87	Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5592-5592.	0.8	2
88	A functional variant in <i>HOXA11-AS</i> , a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. <i>Oncotarget</i> , 2015, 6, 34745-34757.	0.8	98
89	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. <i>Oncotarget</i> , 2015, 6, 44551-44562.	0.8	37
90	A phase I/II trial of multiple dose VB-111 and weekly paclitaxel in recurrent platinum-resistant Mullerian cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5542-5542.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Targeting VEGFRi resistance through HIF-1 α suppression: Phase II clinical trial evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent platinum resistant ovarian cancer.. Journal of Clinical Oncology, 2015, 33, TPS5614-TPS5614.	0.8	1
92	The value of TOP2A as a target for anthracycline-based chemotherapy in advanced endometrial carcinoma (EC): NRG Oncology/Gynecology Oncology Group study.. Journal of Clinical Oncology, 2015, 33, e16509-e16509.	0.8	0
93	Ovarian Cancer: Targeting the Untargetable. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 13-15.	1.8	3
94	Molecular Subtypes of High-Grade Serous Ovarian Cancer: The Holy Grail?. Journal of the National Cancer Institute, 2014, 106, .	3.0	18
95	Risk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples. Journal of the National Cancer Institute, 2014, 106, .	3.0	184
96	Comparative Meta-analysis of Prognostic Gene Signatures for Late-Stage Ovarian Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	110
97	Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature Communications, 2014, 5, 5092.	5.8	112
98	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncology, The, 2014, 15, 1207-1214.	5.1	523
99	Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13948-13953.	3.3	221
100	A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.. Journal of Clinical Oncology, 2014, 32, LBA5500-LBA5500.	0.8	8
101	A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.. Journal of Clinical Oncology, 2014, 32, LBA5500-LBA5500.	0.8	11
102	Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Research, 2014, 34, 811-817.	0.5	46
103	A phase I, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors.. Journal of Clinical Oncology, 2013, 31, 2573-2573.	0.8	11
104	Opsalin: A phase II placebo (Pbo)-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with carboplatin (Cb) and paclitaxel (P).. Journal of Clinical Oncology, 2013, 31, 5516-5516.	0.8	5
105	Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC).. Journal of Clinical Oncology, 2013, 31, 5524-5524.	0.8	22
106	An evaluation of survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group experience.. Journal of Clinical Oncology, 2013, 31, 5534-5534.	0.8	1
107	Achieving quality: Comparing recommendations for cancer care between NCCN and ESMO.. Journal of Clinical Oncology, 2013, 31, 6579-6579.	0.8	0
108	A snapshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.. Journal of Clinical Oncology, 2012, 30, 5029-5029.	0.8	1

#	ARTICLE	IF	CITATIONS
109	OPSA LIN: A phase II placebo-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer treated with carboplatin (Cb) and paclitaxel (P).. Journal of Clinical Oncology, 2012, 30, TPS5112-TPS5112.	0.8	2
110	CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer. Cancer Research, 2011, 71, 5522-5534.	0.4	206
111	Ovarian cancer: individualized and personalized care. Expert Review of Obstetrics and Gynecology, 2010, 5, 409-419.	0.4	3